Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of MedicineGlobeNewsWire • 05/21/23
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of MedicineGlobeNewsWire • 05/21/23
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023PRNewsWire • 05/19/23
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023GlobeNewsWire • 05/19/23
Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims and Supporting Scientific InnovationGlobeNewsWire • 05/18/23
Regeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference TranscriptSeeking Alpha • 05/16/23
Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call TranscriptSeeking Alpha • 05/14/23
Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 EarningsZacks Investment Research • 05/04/23
Regeneron Pharma Dives As Competition Undercuts Its Biggest MoneymakerInvestors Business Daily • 05/04/23
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer ResearchGlobeNewsWire • 05/02/23
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid AngiopathyBusiness Wire • 04/26/23